Orally Administered Targeted Recombinant Beta-Lactamase Prevents Ampicillin-Induced Selective Pressure on the Gut Microbiota: a Novel Approach to Reducing Antimicrobial Resistance

AUTOR(ES)

Harmoinen, Jaana

FONTE

American Society for Microbiology

RESUMO

Antibiotics that are excreted into the intestinal tract promote antibiotic resistance by exerting selective pressure on the gut microbiota. Using a beagle dog model, we show that an orally administered targeted recombinant β-lactamase enzyme eliminates the portion of parenteral ampicillin that is excreted into the small intestine, preventing ampicillin-induced changes to the fecal microbiota without affecting ampicillin levels in serum. In dogs receiving ampicillin, significant disruption of the fecal microbiota and the emergence of ampicillin-resistant Escherichia coli and TEM genes were observed, whereas in dogs treated with ampicillin in combination with an oral β-lactamase, these did not occur. These results suggest a new strategy for reducing antimicrobial resistance in humans.

Documentos Relacionados

• Ampicillin susceptibility and ampicillin-induced killing rate of Escherichia coli.
• Ampicillin-Induced Morphological Alterations of Haemophilus influenzae Type b
• Beta-Lactamase Activity in Ampicillin-Resistant Haemophilus influenzae
• Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors.
• Novel beta-lactamase from Capnocytophaga sp.